Get the Stockscreener App
391.27
0.48%
-1.90
After Hours:
391.28
0.010
+0.00%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $391.27, with a volume of 2.83M.
It is down -0.48% in the last 24 hours and down -4.79% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$393.17
Open:
$393.065
24h Volume:
2.83M
Relative Volume:
1.06
Market Cap:
$211.53B
Revenue:
$37.30B
Net Income/Loss:
$7.80B
P/E Ratio:
27.21
EPS:
14.3793
Net Cash Flow:
$8.60B
1W Performance:
-11.65%
1M Performance:
-4.79%
6M Performance:
+3.79%
1Y Performance:
+39.75%
1-Day Range:
$389.28
$395.55
1-Week Range:
$389.28
$445.81
52-Week Range:
$269.77
$447.03
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
391.27 | 212.56B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,124.21 | 1.00T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
267.08 | 648.55B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
250.91 | 439.62B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
147.53 | 366.28B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
137.48 | 261.73B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Hold |
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Amgen's Imdelltra Sales Surge 115% as Lung-Cancer Combination Me - GuruFocus
Gordon Reid's Past Picks: Amgen, Qualcomm & United Rentals - BNN Bloomberg
Amgen’s Phase III DeLLphi-305 study deliverers strong results - The Pharma Letter
Amgen's Imdelltra scores again in small cell lung cancer - pharmaphorum
Amgen stock falls sharply as trial read-through and Tavneos risk unsettle investors - ad-hoc-news.de
Amgen, AstraZeneca combination improves survival measures in late-stage lung cancer study - Yahoo Finance
Amgen and AstraZeneca report survival improvement in lung cancer trial - Yahoo Finance UK
Amgen Stock Sank 9.6% After Novartis’s Trial Failure and a Tavneos Suspension - TIKR.com
Baird Financial Group Inc. Increases Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen's Forward Multiple Looks Cheap Until You Price The Margins It Assumes - Trefis
Amgen stock heads into the open after a 10.1% drop - ad-hoc-news.de
Amgen and AstraZeneca report positive lung cancer trial results - Investing.com
Amgen and AstraZeneca report positive lung cancer trial results By Investing.com - Investing.com Canada
Amgen Tells 4th Circ. No Point In Keeping CareFirst Suit Alive - Law360
Amgen-AstraZeneca lung cancer drug combo boosts survival in late-stage trial - WTVB
A Look at Amgen Inc (AMGN) After 10.1% Decline -- GF Value $365. - GuruFocus
AMGN Looks 7.5% Overvalued on GF Value™ After Late-Stage Trial C - GuruFocus
Stock Market Today, Sept. 8: Stocks Slide Amid Surging Oil Prices, Persistent Geopolotical Tenisons - The Motley Fool
Stocks to Watch Recap: Intel, Amgen, Qualcomm, Rigetti - WSJ
Amgen slides 10% amid olpasiran read-through concerns (AMGN:NASDAQ) - Seeking Alpha
Amgen, Novartis, Qualcomn, Corning, Lumentum, and More Stocks That Explain Today’s Market - Barron's
AMGN Looks 8.2% Overvalued on GF Value™ - GuruFocus
Amgen-AstraZeneca drug combo helps lung cancer patients live longer in late-stage study - Reuters
Amgen: Why Rivals' Cholesterol Drug Failure Is Bad News For The Pharma (Rating Downgrade) - Seeking Alpha
Amgen Drops 9.0% Amid Sector-Wide Selling - AlphaStreet
QUICK SPARK: Amgen Stock Eyes Worst Day Since October 2000 - TradingView
S&P 500, Nasdaq Slip as $98 Brent Reignites Inflation Fears: Stock Market Today - Benzinga
Amgen Falls 10% as Novartis Trial Failure Clouds a Cholesterol Drug Class; NVS Stock Drops 14% - finance.yahoo.com
Amgen, Salesforce Share Losses Contribute To Dow's 525-Point Fall - Moomoo
What's Going On With Amgen Stock Tuesday? - Benzinga
Amgen caught in the crossfire of Novartis' failure - marketscreener.com
Amgen (NASDAQ:AMGN) Shares Gap DownHere's Why - MarketBeat
Amgen (NASDAQ:AMGN): What’s Driving the Fresh Market Buzz? - Kalkine Media
Disappointing Clinical Trial Results Are Dragging Novartis, Amgen and the Dow Lower Tuesday - Yahoo Finance
AstraZeneca and Amgen clear a milestone in small cell lung cancer - marketscreener.com
Why Amgen Stock Is Down 8.7% And What's Next After Lp(a) Drug Doubts - simplywall.st
Amgen drops on Novartis trial setback for heart therapy; BMO downgrades - Seeking Alpha
Amgen Announces Landmark Results From The Phase 3 DeLLphi-305 Study Demonstrating Statistically Significant And Clinically Meaningful Improvement In Overall Survival With IMDELLTRA In Combination With Imfinzi Compared To Durvalumab Alone - marketscreener.com
Amgen Inc Stock (AMGN) Moved Down by 8.33% on Sep 8: A Full Analysis - TradingKey
Why Amgen Stock Is Getting Hit by a Novartis Trial Setback - Barron's
AMGN Reiterated by Cantor Fitzgerald -- Price Target Maintained at $400 - GuruFocus
This Best Buy Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday - Benzinga
Amgen-AstraZeneca cancer drug combo hits main survival goal in late-stage trial - marketscreener.com
Novartis pelacarsen Lp(a) trial fails, raising doubts for Amgen, Lilly - qz.com
IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER - PR Newswire
Amgen (NASDAQ:AMGN) Receives "Neutral" Rating from Cantor Fitzgerald - MarketBeat
Is AMGN Overvalued? DCF Says Worth $296 - GuruFocus
BMO lowers Amgen, BioNTech to Market Perform as risk-reward shifts - Investing.com Canada
Amgen Shares Fall as Investors Assess Novartis Lp(a) Trial Result and BMO Downgrade - Yahoo Finance
Novartis Faces Setback with Pelacarsen Clinical Trial, Impacting Competitors - GuruFocus
Why Amgen Stock Is Dropping After Swiss Rival’s Trial Setback - Barron's
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amgen Inc Stock (AMGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Khosla Rachna | SVP, Business Development |
Aug 11 '26 |
Sale |
412.57 |
2,000 |
825,134 |
6,404 |
| Khosla Rachna | SVP, Business Development |
Aug 13 '26 |
Sale |
416.43 |
1,252 |
521,365 |
6,404 |
1.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):